Infectious Disease

Competition may threaten Gilead as market leader

Competition may threaten Gilead as market leader

By

Even as Gilead prepares to launch a third hepatitis-C product, drugs offering better antimicrobial resistance are angling for their own moments in the spotlight.

Drugmakers renew interest in antibiotic development

Drugmakers renew interest in antibiotic development

By

The goal is to develop medications that move beyond the high-toxicity and low-efficacy profiles of older drugs.

TMC's McGuire preps CRE antibiotic for market

TMC's McGuire preps CRE antibiotic for market

By

The Medicines Company's commercial lead for infection disease care talks about its breakthrough antidote for carbapenem-resistant enterobacteriaceae.

OPINION

Email Newsletters